| 9.5 0.5 (5.56%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.94 | 1-year : | 13.95 |
| Resists | First : | 10.22 | Second : | 11.94 |
| Pivot price | 9.02 |
|||
| Supports | First : | 8.14 | Second : | 6.84 |
| MAs | MA(5) : | 8.96 |
MA(20) : | 8.68 |
| MA(100) : | 8.09 |
MA(250) : | 6.71 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 63.7 |
D(3) : | 61.2 |
| RSI | RSI(14): 58.8 |
|||
| 52-week | High : | 10.98 | Low : | 3.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KPTI ] has closed below upper band by 17.8%. Bollinger Bands are 51.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.22 - 10.27 | 10.27 - 10.31 |
| Low: | 8.93 - 8.98 | 8.98 - 9.03 |
| Close: | 9.41 - 9.5 | 9.5 - 9.57 |
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Wed, 03 Jun 2026
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 - Karyopharm
Mon, 01 Jun 2026
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Wed, 27 May 2026
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet - Yahoo Finance
Thu, 07 May 2026
Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 - Karyopharm
Tue, 21 Apr 2026
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting - PR Newswire
Fri, 17 Apr 2026
RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term Performance - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 83.4 (%) |
| Shares Short | 5,280 (K) |
| Shares Short P.Month | 5,720 (K) |
| EPS | -16.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -16 |
| Profit Margin | -129.1 % |
| Operating Margin | -76.4 % |
| Return on Assets (ttm) | -40.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 16.7 % |
| Gross Profit (p.s.) | 0.89 |
| Sales Per Share | 6.66 |
| EBITDA (p.s.) | -3.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.58 |
| PEG Ratio | 0 |
| Price to Book value | -0.6 |
| Price to Sales | 1.42 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|